Deciding on a GLP-1 is not a matter of BMI alone. It depends on the degree of adiposity and the comorbidities present, what has already been tried, the goal, contraindications (such as a history of medullary thyroid cancer, or pregnancy), eating behaviour, cost and access, and the long-term plan. This page sets out those factors as preparation for a clinical conversation; it is education, not a prescription.
GLP-1 and dual-incretin medicines (semaglutide, tirzepatide) are genuinely effective for many people, and they are also over-hyped, sometimes prescribed where they do not fit, and not suitable for everyone. → GLP-1 & Incretin Medications hub
Eight factors that drive the decision
Step 1 · Adiposity and comorbidities
The starting point is not a number on the scale but whether excess adiposity is affecting health. Clinicians generally consider anti-obesity pharmacotherapy for people with obesity, or with overweight plus a weight-related condition (type 2 diabetes or prediabetes, hypertension, dyslipidaemia, fatty liver, sleep apnea, established cardiovascular disease).
- The greater the comorbidity burden, the more a medication's benefits beyond weight matter — for example semaglutide's ~20% reduction in major cardiovascular events in people with established CVD and overweight/obesity without diabetes (SELECT), or tirzepatide's OSA approval. (Grade A 🟢)
- Wanting to lose a few pounds before an event is a different question from excess weight harming metabolic health. → What Is Obesity?
To discuss: which weight-related conditions are present, and whether a GLP-1 would help those specifically rather than the scale alone.
Step 2 · What has already been tried
Medication is not a confession of failure, and lifestyle is not a probationary period before real treatment. The history still matters: which nutrition, activity, sleep and behavioural approaches were genuinely tried, for how long, and what happened. → The WeightExperts Clinical Approach
- Obesity is biologically defended, so regain after lifestyle change is common and is not a willpower failure. → Why Weight Is So Hard to Lose
- Medication works best alongside nutrition and resistance training rather than instead of them. → Nutrition · Exercise & Muscle
To discuss: what has actually been tried, and whether the plan combines medication with lifestyle rather than replacing it.
Step 3 · The goal
The goal is rarely the scale. It may be diabetes prevention or remission, cardiovascular-risk reduction, liver-fibrosis stabilization, sleep apnea, fertility (PCOS), mobility, or quality of life. Different goals point to different drugs, doses and measures of success.
- For cardiovascular-risk reduction with established disease, the evidence favours specific agents. For OSA, tirzepatide holds the indication. For MASH with F2–F3 fibrosis, semaglutide 2.4 mg is approved.
To discuss: the real goal, and which outcome other than weight would show that treatment is working.
Step 4 · Contraindications and cautions
Some factors are genuine reasons not to take these drugs, or reasons for caution. Each is reviewed with a clinician before starting.
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 — a boxed-warning contraindication for GLP-1/incretin agents. (Grade A 🟢)
- History of pancreatitis — caution; individualized.
- Pregnancy, or trying to conceive — avoid; some agents should be stopped well before conception given a long half-life (about two months for semaglutide). → see Step 6.
- Prior severe reaction, certain gallbladder or gastrointestinal conditions, gastroparesis — individualized cautions. → GLP-1 Side Effects
To discuss: whether any of these apply. A single one — MTC or MEN2, for instance — can take these drugs off the table.
Step 5 · Eating behaviour
Eating patterns shape both suitability and safety. GLP-1s reduce appetite and "food noise," which many people find profound, but they are not a treatment for an eating disorder.
- Where binge-eating disorder, a restrictive-eating history or another eating disorder is present, that needs its own assessment and care; medication may still have a role but should not replace psychological treatment. (Grade B 🟡)
- Reduced appetite makes adequate protein and nutrition more important, not less. → GLP-1 & Muscle Loss
To discuss: whether a disordered-eating pattern should be evaluated and supported first, or alongside.
Step 6 · Pregnancy plans
GLP-1/incretin agents are avoided in pregnancy, which makes this a distinct branch of the decision for anyone who might conceive.
- Plan to stop before conception — about two months ahead for semaglutide, given its half-life. (Grade A 🟢)
- Tirzepatide has a labelled oral-contraceptive interaction; a backup or non-oral contraceptive method is advised for about four weeks when starting or increasing the dose. (Grade A 🟢) → Tirzepatide
- Where conception is planned soon — in some PCOS scenarios, for example — the plan often focuses elsewhere entirely.
To discuss: pregnancy, breastfeeding or pregnancy plans, and whether contraception is adequate.
Step 7 · Access and cost
These medications are expensive, coverage varies, and stopping usually leads to regain, so access has to be sustainable rather than available only at the start.
- If cost or coverage will force stopping within a few months, that changes the calculation — and makes a compounded alternative tempting, with its own safety and quality concerns. (Grade B 🟡)
- A plan that can be sustained beats a stronger plan that will have to be abandoned. → Weight Regain & Maintenance
To discuss: whether this is affordable and accessible for long enough to benefit, and what happens if it is not.
Step 8 · Long-term strategy
Obesity behaves like a chronic condition. These drugs work while they are taken, and stopping predictably leads to regain — in the STEP 1 extension, ~two-thirds of lost weight regained within ~1 year off drug. The operative question is therefore not whether to start but what the long-term plan is.
- Is ongoing therapy acceptable, or is a deliberate maintenance strategy planned? → Weight Regain
- Would surgery fit the degree of obesity and the goals better? Medication and surgery are different tools rather than rivals.
To discuss: the multi-year plan, and how muscle and results will be maintained.
What this amounts to
Taken together, these factors produce a list of considerations to raise at an appointment — for example, that a weight-related condition is present and no listed contraindication applies, but pregnancy is planned within a year and coverage is uncertain. Each branch links to the evidence behind it. There is deliberately no result that reads "you need Ozempic": a medication is chosen, or not, by a patient and a clinician weighing all of this together. → Request an appointment
What the evidence says: choosing a GLP-1
- What we know: GLP-1/incretin agents produce substantial average weight loss and, for specific agents and populations, real outcome benefits (CV events, OSA, MASH). Contraindications (MTC/MEN2, pregnancy) are well defined.
- What we think: the decision should be driven by comorbidities, goals, contraindications, eating behaviour, pregnancy plans and sustainable access rather than by BMI alone.
- What we don't know: very long-term outcomes for some newer agents, and the best individual match among expanding options.
- What patients should do: use this page to prepare, then decide with a clinician. No online tool should hand out a prescription.
Questions patients ask
Do I qualify for a GLP-1 if I don't have diabetes?
Possibly — these agents are approved for chronic weight management in obesity, or in overweight with a weight-related condition, independent of diabetes. Whether one suits a particular person depends on the factors above. Grade A 🟢 → Semaglutide
What would rule me out?
A personal or family history of medullary thyroid cancer or MEN2 is a boxed-warning contraindication; pregnancy or planned pregnancy means avoiding these drugs; a history of pancreatitis and certain GI conditions are cautions. Each is reviewed with a clinician. Grade A 🟢 → GLP-1 Side Effects
Can I take a GLP-1 if I'm trying to get pregnant?
No. GLP-1/incretin agents are avoided in pregnancy and should be stopped before conception — about two months ahead for semaglutide. Tirzepatide also has an oral-contraceptive interaction to plan around. Grade A 🟢 → Tirzepatide
Do I have to take it forever?
Often, to keep the benefit — obesity behaves like a chronic condition, and stopping usually leads to regain, about two-thirds of lost weight within a year in trials. Some people transition to a maintenance strategy, but a short course that ends the problem is rare. Grade A 🟢 → Weight Regain
Is a GLP-1 better than surgery?
Neither is universally better. Surgery gives larger, more durable average loss and strong diabetes remission but is a procedure with lifelong follow-up; GLP-1s avoid surgery but require ongoing use. The choice depends on the degree of obesity, the comorbidities and the goal. Grade A 🟢 → Bariatric Surgery
Should I use a GLP-1 if I have binge-eating disorder?
Possibly, but not as a substitute for treating the disorder. Binge-eating disorder needs its own psychological and sometimes pharmacological care; a GLP-1 may have a role alongside it, assessed carefully. Grade B 🟡 → Mental Health & Obesity
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: STEP and SURMOUNT programmes; SELECT; SURMOUNT-OSA; FDA labelling (boxed warning MTC/MEN2; pregnancy; tirzepatide oral-contraceptive interaction); AACE/obesity-medicine guidance. Educational only; not a prescription and not individualized medical advice.
